The
Company excluded the following from the computation of diluted net loss per share attributable to common shareholders for the three months
ended September 30, 2025 and 2024 because including them would have had an anti-dilutive effect:
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Three Months Ended September 30 | | |
Nine Months Ended September 30 | | |
| |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Shares issuable upon exercise of stock options | |
| 1,759,211 | | |
| 286,086 | | |
| 1,759,211 | | |
| 286,086 | |
| Warrants to purchase common stock outstanding | |
| 350,000 | | |
| 350,000 | | |
| 350,000 | | |
| 350,000 | |
| Total | |
| 2,109,211 | | |
| 636,086 | | |
| 2,109,211 | | |
| 636,086 | |
| Anti-dilutive shares | |
| 2,109,211 | | |
| 636,086 | | |
| 2,109,211 | | |
| 636,086 | |
|